Skip to content
value.today

Theseus Pharmaceuticals, Inc.

🇺🇸 New York, New York, USATechnologyFounded 2017
Total raised
$117 M
2 rounds on record
Latest round
$95 M
Jan 2021
First round on record
Jun 2018
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Theseus Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2021$95 MNo. 2$50 to $250 million

Theseus Pharmaceuticals, Inc.: Raise no. 2, Jan 2021

Investors in this round

16 investors had bought by the notice of Feb 4, 2021: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Theseus Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$95 M of $100 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Iain Dukes · Executive Officer, Director
  • Carl C. Gordon · Director
  • Michael C. Rome · Director
  • William C. Shakespeare · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Iain Dukes, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 4, 2021. Read the notice at the SEC.

equitySEC
Jun 2018$22 MNo. 1$10 to $50 million

Theseus Pharmaceuticals, Inc.: Raise no. 1, Jun 2018

Investors in this round

3 investors had bought by the notice of Feb 4, 2021: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Theseus Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Iain Dukes · Executive Officer, Director
  • Carl C. Gordon · Director
  • Michael C. Rome · Director
  • William C. Shakespeare · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Iain Dukes, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 4, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Theseus Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).

    SEC Form D · Feb 2021

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Feb 2021

That is all the official record says: Theseus Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

11 named in official filings. Open an investor to see everything it has backed.

Investors in Theseus Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Ariad Pharmaceuticals IncCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Omega Fund VI GP, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Omega Fund VI GP Manager, Ltd.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Omega Fund VI, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
OrbiMed Capital GP VII LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
OrbiMed Genesis GP LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Rock Springs Capital LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Rock Springs Capital Management LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Rock Springs Capital Master Fund LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Takeda Pharmaceutical Co LTDCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 16 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Theseus Pharmaceuticals, Inc.
NameRoleNamed in
Iain DukesExecutive officerFeb 2021
Carl C. GordonDirectorFeb 2021
Iain DukesDirectorFeb 2021
Michael C. RomeDirectorFeb 2021
William C. ShakespeareDirectorFeb 2021